Payment overview · 2025
General Payments
$1,643.82
95 reported records · 22 companies
Healthcare provider profile · identity verified
John L Palcheff, DO
Allopathic & Osteopathic Physicians|Family Medicine · JERSEYVILLE, IL · NPI 1760442032
Verified facts
What the public records show
CMS Open Payments records show John L Palcheff, DO received $1,643.82 in general payments during 2025 across 95 reported records.
ABBVIE INC. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trelegy Ellipta by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $269.75 | 16.4% | 20 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $254.05 | 15.4% | 12 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $179.46 | 10.9% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $177.98 | 10.8% | 12 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $126.73 | 7.7% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $112.00 | 6.8% | 6 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $91.68 | 5.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.53 | 3.7% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.04 | 3.2% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $48.80 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $46.91 | 2.9% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $28.65 | 1.7% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $25.55 | 1.6% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.77 | 1.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.51 | 1.4% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.85 | 1.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.00 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.80 | 1.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.78 | 1.1% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $14.76 | 0.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $14.66 | 0.9% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $13.56 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,643.82 | 95 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $254.05 | 12 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $183.84 | 14 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $177.98 | 12 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $150.24 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $139.38 | 10 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.11 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $112.00 | 6 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $91.68 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $86.91 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $85.91 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $85.91 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $61.53 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.33 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $48.80 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $46.91 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $38.60 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.94 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $28.65 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $25.55 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.77 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.80 | 1 | 2025 |
Source payment records
|
|||||
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $17.78 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $14.76 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $14.66 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
47 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 415 | 97 |
| Lisinopril | Lisinopril | 400 | 93 |
| Omeprazole | Omeprazole | 317 | 78 |
| Levothyroxine Sodium | Levothyroxine Sodium | 299 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 276 | 64 |
| Meloxicam | Meloxicam | 240 | 61 |
| Hydrochlorothiazide | Hydrochlorothiazide | 211 | 49 |
| Amlodipine Besylate | Amlodipine Besylate | 188 | 46 |
| Gabapentin | Gabapentin | 161 | 39 |
| Tramadol Hcl | Tramadol Hcl | 155 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 138 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 30 |
| Potassium Chloride | Potassium Chloride | 131 | 27 |
| Metformin Hcl | Metformin Hcl | 128 | 41 |
| Allopurinol | Allopurinol | 125 | 32 |
| Famotidine | Famotidine | 125 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 124 | 34 |
| Trazodone Hcl | Trazodone Hcl | 123 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 117 | 25 |
| Losartan Potassium | Losartan Potassium | 115 | 32 |
| Donepezil Hcl | Donepezil Hcl | 114 | 15 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 30 |
| Furosemide | Furosemide | 107 | 22 |
| Memantine Hcl | Memantine Hcl | 101 | suppressed |
| Simvastatin | Simvastatin | 101 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 97 | 26 |
| Buspirone Hcl | Buspirone Hcl | 95 | 17 |
| Sertraline Hcl | Sertraline Hcl | 95 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 16 |
| Eliquis | Apixaban | 84 | 13 |
| Carvedilol | Carvedilol | 77 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 73 | 13 |
| Alprazolam | Alprazolam | 70 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 68 | 11 |
| Methylprednisolone | Methylprednisolone | 63 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 60 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 24 |
| Januvia | Sitagliptin Phosphate | 59 | suppressed |
| Ezetimibe | Ezetimibe | 53 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 12 |
| Mirtazapine | Mirtazapine | 52 | 13 |
| Glipizide | Glipizide | 51 | 16 |
| Azithromycin | Azithromycin | 48 | 41 |
| Jardiance | Empagliflozin | 47 | 15 |
| Celecoxib | Celecoxib | 46 | 11 |
| Baclofen | Baclofen | 45 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 45 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 40 | 15 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 38 | 28 |
| Chlorzoxazone | Chlorzoxazone | 36 | 17 |
| Lactulose | Lactulose | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Trulicity | Dulaglutide | 33 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 30 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 29 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 28 | suppressed |
| Ketoconazole | Ketoconazole | 27 | 16 |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 25 | suppressed |
| Levofloxacin | Levofloxacin | 24 | 20 |
| Lovastatin | Lovastatin | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | 12 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Cephalexin | Cephalexin | 20 | 18 |
| Glimepiride | Glimepiride | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 13 | suppressed |
| Atenolol | Atenolol | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Orphenadrine Citrate Er | Orphenadrine Citrate | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Renvela | Sevelamer Carbonate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,643.82 · 95 records | ABBVIE INC. | AUSTEDO XR, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FREESTYLE LIBRE 3, FUROSCIX, INGREZZA, INSPIRE, Jornay PM, KEVEYIS, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SPRAVATO, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR, Wegovy, ZAVZPRET, ZENPEP, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error